Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
Implementation of genetic testing in breast cancer patients
Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC
Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women
Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer
Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer
Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA
QUANTUM-R: Transfusion independence in patients with FLT3-ITD-mutated R/R AML treated with quizartinib or salvage chemotherapy
Safety and efficacy of the novel BTK inhibitor zanubrutinib in patients with CLL/SLL
Ibrutinib plus venetoclax for the first-line treatment of CLL/SLL: Results from the CAPTIVATE study
KEYNOTE-522 updates: Pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast cancer